Benzinga | Jan 20, 2021 07:05AM EST

Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology

Eloxx Pharmaceuticals, Inc., (NASDAQ:ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that a scientific manuscript titled: "Phase 1 Renal Impairment Trial Results Enable Targeted Individualized Dosing of ELX-02 in Nephropathic Cystinosis Patients," has been published in the Journal of Clinical Pharmacology.

"We are pleased that our scientific manuscript on the results of our Phase 1 renal impairment trial which defined the relationship of eGFR and drug exposure and urinary clearance in patients with renal impairment has been published in the Journal of Clinical Pharmacology," said Dr. Thomas Haverty, Chief Medical Officer at Eloxx Pharmaceuticals. "ELX-02 was well tolerated by patients with renal insufficiency and nephropathic cystinosis patients and exhibits a consistent pharmacokinetic profile across increasing degrees of renal insufficiency with reduced clearance, increased exposure, and prolonged renal elimination proportional to eGFR. The data from the renal impairment study enabled the development of an eGFR-PK model of ELX-02 which was successfully used to implement individualized daily dosing of ELX-02 in a Phase 2a study in patients with nephropathic cystinosis to achieve a weekly targeted exposure." These results further support our ongoing Phase 2 program in cystic fibrosis and IND-enabling studies in autosomal dominant polycystic kidney disease,"